Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours Β· Estimated delivery Aug 21 - Aug 26
PMID: 10404017 Nass, R., et al
This is an area where I see the highest level of need among my patients
A larger clinical trial randomly assigned more than 500 patients with type 2 diabetes and symptomatic peripheral neuropathy to one of the following treatments: (i) 600 mg/day of intravenous lipoic acid for three weeks followed by 1,800 mg/day of oral lipoic acid for six months, (ii) 600 mg/day of intravenous lipoic acid for three weeks followed by oral placebo for six months, or (iii) intravenous placebo for three weeks followed by oral placebo for six months (76)
Switching to SCIG The majority of physicians favor subcutaneous immunoglobulin (SCIG) over IVIG for most patients who experience a headache and may encourage making a transition
T cell Mitochondria play a critical role in T cell activation and differentiation
